Begin treating patients in the ALLIANCE pivotal trial for the SAPIEN X4 system
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 26 Apr 2022
- Due
- 30 Jun 2022
- Delivered
- Q2 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Edwards also remains on track to begin treating patients in the second quarter in the ALLIANCE pivotal trial for the company's next generation TAVR technology, the SAPIEN X4 system.”
What we found
Evidence strength A What the grades mean
Edwards reported in its July 2022 8-K and 10-Q that it began treating patients in the ALLIANCE trial for SAPIEN X4 during the second quarter of 2022.
-
A Edwards Lifesciences 8-K filed 2022-07-28
“Edwards also began treating patients in the ALLIANCE pivotal trial for the company’s next-generation TAVR technology, the SAPIEN X4 system.” ✓ confirmed on the page
-
A Edwards Lifesciences 10-Q filed 2022-07-29
“During the second quarter of 2022, we began treating patients in our ALLIANCE pivotal trial, studying our next-generation TAVR technology, SAPIEN X4.” ✓ confirmed on the page
-
A Edwards Lifesciences 10-K filed 2023-02-13
“During the second quarter of 2022, we began treating patients in our ALLIANCE pivotal trial, studying our next-generation TAVR technology, SAPIEN X4” ✓ confirmed on the page
-
A Edwards Lifesciences 10-Q filed 2023-07-28
“In July 2023, we announced the restart of enrollment in our pivotal trial, ALLIANCE, designed to study our next generation TAVR technology, SAPIEN X4.” ✓ confirmed on the page
Market reaction: the shares moved -8.3% against the S&P 500 over the three sessions around the disclosure (27 Jul 2022 to 1 Aug 2022). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Start of patient treatment in ALLIANCE pivotal trial
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Edwards Lifesciences? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-EW-005536 · Corrections policy